* Madrigal Pharmaceuticals Inc MDGL.OQ reported a
quarterly
adjusted loss of $7.38 per share for the quarter ended in
March, lower than the same quarter last year, when the company
reported EPS of $-4.23. The mean expectation of
thirteen analysts for the quarter was for a loss of $6.28 per
share. Wall Street expected results to range from $-7.34
to $-4.86 per share.
* Reported revenue was zero; analysts expected zero.
* Madrigal Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $7.38.
* The company reported a quarterly loss of $147.54 million.
* Madrigal Pharmaceuticals Inc shares had fallen by 11.8%
this
quarter and gained 1.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 24.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Madrigal
Pharmaceuticals Inc is $390.00
This summary was machine generated from LSEG data May 7 at 01:52
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -6.28 -7.38 Missed
Dec. 31 2023 -5.28 -5.68 Missed
Sep. 30 2023 -4.93 -5.34 Missed
Jun. 30 2023 -4.58 -4.69 Missed